

Purified anti-mouse CD11c Antibody

Catalog# / Size	117301 / 50 µg 117302 / 500 µg
Clone	N418
Regulatory Status	RUO
Other Names	αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype	Armenian Hamster IgG
Description	CD11c is a 150 kD glycoprotein also known as α _X integrin, CR4, and p150. CD11c forms a α _X β ₂ heterodimer with β ₂ integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The α _X β ₂ integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Armenian Hamster
Immunogen	Mouse spleen dendritic cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	FC - Quality tested CyTOF® - Verified IP, IHC - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Additional reported applications (for the relevant formats) include: immunoprecipitation ³ , immunohistochemical staining of acetone-fixed frozen sections ³ , immunofluorescence microscopy ^{5,9} (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections ¹⁰), and spatial biology (IBEX) ^{22,23} .

Application References

1. Granucci F, *et al.* 1997. *J. Immunol.* 159:1794.
2. Stokes RW, *et al.* 1998. *J. Immunol.* 160:5514.
3. Metlay JP, *et al.* 1990. *J. Exp. Med.* 171:1753. (IHC, IP)
4. Ma XT, *et al.* 2006. *Cancer Research* 66:1169.
5. Chin RK, *et al.* 2006. *J. Immunol.* 177:290. (IF)
6. Cervantes-Barragan L, *et al.* 2007. *Blood* 109:1131. (FC) [PubMed](#)
7. Turnquist HR, *et al.* 2007. *J. Immunol.* 178:7018. (FC) [PubMed](#)
8. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, *et al.* 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, *et al.* 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, *et al.* 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, *et al.* 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, *et al.* 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, *et al.* 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, *et al.* 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)

17. Eisenach PA, *et al.* 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, *et al.* 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, *et al.* 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Hernández-Santana YE, *et al.* 2020. *Life Sci Alliance.* 3:00. [PubMed](#)
2. Martínez LE, *et al.* 2020. *J Virol.* 94:00:00. [PubMed](#)
3. Dallari S, *et al.* 2017. *Nat Commun.* 8:14830. [PubMed](#)
4. Arnold IC, *et al.* 2019. *PLoS Pathog.* 15:e1007866. [PubMed](#)
5. Hutton C, *et al.* 2021. *Cancer Cell.* 39:1227. [PubMed](#)
6. Aguilar EG, *et al.* 2021. *Blood Adv.* 5:4219. [PubMed](#)
7. Owen KL, *et al.* 2020. *EMBO Rep.* 21:e50162. [PubMed](#)
8. Kobayashi A, *et al.* 2021. *Front Immunol.* 12:650856. [PubMed](#)
9. Paterson MJ, *et al.* 2020. *PLoS Pathog.* 16:e1008733. [PubMed](#)
10. Bruce DW, *et al.* 2021. *Blood Adv.* 5:4578. [PubMed](#)
11. Mendes A, *et al.* 2021. *Life Sci Alliance.* 4:00. [PubMed](#)
12. Fahlén-Yrliid L, *et al.* 2009. *J Immunol.* 183:5032. [PubMed](#)
13. Osterholzer J, *et al.* 2009. *J Immunol.* 183:8044. [PubMed](#)
14. Sun L, *et al.* 2020. *Nat Commun.* 2.229166667. [PubMed](#)
15. Trittel S, *et al.* 2019. *Sci Rep.* 9:16362. [PubMed](#)
16. Mazar R, *et al.* 2018. *Proc Natl Acad Sci U S A.* 115:E733. [PubMed](#)
17. Bhatt K, *et al.* 2018. *mSphere.* 3:e00352. [PubMed](#)
18. Chartrand K, *et al.* 2018. *Front Immunol.* 1.642361111. [PubMed](#)
19. Bajarña S, *et al.* 2021. *Front Immunol.* 11:577718. [PubMed](#)
20. Wan Mohd Zawawi WFA, *et al.* 2021. *Sci Rep.* 11:10278. [PubMed](#)
21. Khan KA, *et al.* 2020. *NPJ Breast Cancer.* 6:29. [PubMed](#)
22. Bachran C, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-17948-0. [PubMed](#)
23. Rieck M, *et al.* 2017. *Eur J Immunol.* 47:677. [PubMed](#)
24. Dubrot J, *et al.* 2018. *Life Sci Alliance.* 1:e201800164. [PubMed](#)
25. Field CS, *et al.* 2018. *Oncoimmunology.* 7:e1376154. [PubMed](#)
26. Wang W, *et al.* 2018. *Cancer Cell.* 34:757. [PubMed](#)
27. Arnold IC, *et al.* 2018. *J Exp Med.* 215:2055. [PubMed](#)
28. Prado C, *et al.* 2021. *J Neuroinflammation.* 18:292. [PubMed](#)
29. Fang C, *et al.* 2020. *Cell Mol Immunol.* . [PubMed](#)
30. Bonnefoy F, *et al.* 2018. *Front Immunol.* 2.170833333. [PubMed](#)
31. Cao Q, *et al.* 2018. *Am J Physiol Renal Physiol.* 314:F561. [PubMed](#)
32. Periasamy S, *et al.* 2017. *Nat Commun.* 8:15564. [PubMed](#)
33. Lechner AJ *et al.* 2017. *Cell stem cell.* 21(1):120-134 . [PubMed](#)
34. Mayer JU, *et al.* 2020. *Front Immunol.* 11:592325. [PubMed](#)
35. Tal MC, *et al.* 2020. *MBio.* 11:00. [PubMed](#)
36. Hitchcock JR, *et al.* 2020. *FEBS J.* 287:250. [PubMed](#)
37. McLeod RL, *et al.* 2018. *Oncotarget.* 9:34459. [PubMed](#)
38. Kitai Y, *et al.* 2017. *J Immunol.* 198:1649. [PubMed](#)
39. Sutton C, *et al.* 2017. *Nat Commun.* 10.1038/s41467-017-02111-0. [PubMed](#)
40. Lee JH, *et al.* 2022. *iScience.* 25:104166. [PubMed](#)
41. Jackson JW, *et al.* 2021. *Mol Ther Oncolytics.* 22:444. [PubMed](#)
42. Mayer KA, *et al.* 2021. *FASEB J.* 35:e21217. [PubMed](#)
43. Delgobo M, *et al.* 2021. *Front Immunol.* 12:584538. [PubMed](#)
44. Peng V, *et al.* 2020. *J Biol Chem.* 295:14866. [PubMed](#)
45. Aparicio-Domingo P, *et al.* 2015. *J Exp Med.* 101084/jm20150318. [PubMed](#)
46. Shimokawa C *et al.* 2017. *Immunity.* 46(5):863-874 . [PubMed](#)
47. Nolin JD, *et al.* 2017. *JCI Insight.* 2:e94929. [PubMed](#)
48. Sun H, *et al.* 2018. *J Cell Biol.* 217:1453. [PubMed](#)
49. Chen S, *et al.* 2018. *Immunohorizons.* 0.345138889. [PubMed](#)
50. Khan KA, *et al.* 2020. *NPJ Breast Cancer.* 6:29. [PubMed](#)
51. Hilligan KL, *et al.* 2020. *Nat Commun.* 11:5637. [PubMed](#)
52. Suzuki Y, *et al.* 2021. *FEBS Open Bio.* 11:2619. [PubMed](#)
53. Yan J, *et al.* 2020. *Cancer Immunol Res.* 8:356. [PubMed](#)
54. Chen L, *et al.* 2020. *Front Immunol.* 11:584458. [PubMed](#)
55. Manni M, *et al.* 2018. *Nat Immunol.* 1.074305556. [PubMed](#)
56. Stacey MA, *et al.* 2017. *J Clin Invest.* 127:1463. [PubMed](#)
57. Fu H, *et al.* 2019. *Front Immunol.* 10:271. [PubMed](#)
58. Snell LM, *et al.* 2018. *Immunity.* 49:678. [PubMed](#)
59. Mrdjen D *et al.* 2018. *Immunity.* 48(2):380-395 . [PubMed](#)
60. He LD, *et al.* 2021. *EMBO Rep.* 22:e52196. [PubMed](#)
61. Sun Y, *et al.* 2022. *Nat Commun.* 13:3916. [PubMed](#)
62. Molica F, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-14130-4. [PubMed](#)
63. Gartlan KH, *et al.* 2019. *Blood Adv.* 2.110416667. [PubMed](#)
64. Mainini F, *et al.* 2018. *Nucleic Acid Ther.* 28:225. [PubMed](#)
65. Lai JF, *et al.* 2020. *J Allergy Clin Immunol.* 146:1406. [PubMed](#)
66. Liu H, *et al.* 2020. *J Immunol.* 205:1207. [PubMed](#)
67. Wang Y, *et al.* 2021. *Sci Transl Med.* 13:. [PubMed](#)
68. Brown IK, *et al.* 2021. *PLoS Pathog.* 17:e1009602. [PubMed](#)
69. Wei S, *et al.* 2019. *Virulence.* 0.588888889. [PubMed](#)

70. Tsubaki T, *et al.* 2018. *Oncotarget*. 9:11209. [PubMed](#)
71. Borges TJ, *et al.* 2018. *Nat Commun*. 9:3482. [PubMed](#)
72. Enders M, *et al.* 2020. *J Immunol*. 204:87. [PubMed](#)
73. Lee JY, *et al.* 2018. *Front Immunol*. 0.678472222. [PubMed](#)
74. Nascimento DC, *et al.* 2017. *Nat Commun*. 8:14919. [PubMed](#)
75. Shin J, *et al.* 2018. *Diabetes*. 67:1068. [PubMed](#)
76. Majer O, *et al.* 2019. *Nature*. 575:366. [PubMed](#)
77. Pericolini E, *et al.* 2008. *J Leukoc Biol*. 83:1286. [PubMed](#)
78. Johnson SA, *et al.* 2021. *Eur J Immunol*. 51:3228. [PubMed](#)
79. Schuler CF, *et al.* 2020. *Allergy*. 75:2279. [PubMed](#)
80. Lim CS, *et al.* 2020. *Front Immunol*. 11:1186. [PubMed](#)
81. Tao H, *et al.* 2021. *Front Immunol*. 12:623280. [PubMed](#)
82. Briot C, *et al.* 2021. *Immunity*. .: [PubMed](#)
83. Murakami R, *et al.* 2013. *PLoS One*. 8:73270. [PubMed](#)
84. Matsuo K, *et al.* 2018. *J Invest Dermatol*. 138:1764. [PubMed](#)
85. King IL, *et al.* 2017. *Mucosal Immunol*. 10:1160. [PubMed](#)
86. Denny JE, *et al.* 2019. *Sci Rep*. 2.786111111. [PubMed](#)
87. Nagatake T, *et al.* 2018. *Int Immunol*. 30:471. [PubMed](#)
88. Oyarce K, *et al.* 2018. *Front Immunol*. 9:112. [PubMed](#)
89. Guilliams M, *et al.* 2022. *Cell*. 185:379. [PubMed](#)
90. Chen HW, *et al.* 2021. *Biomedicines*. 9.: [PubMed](#)
91. Cepeda JR, *et al.* 2020. *MAbs*. 12:1836714. [PubMed](#)
92. Penkert RR, *et al.* 2020. *Obesity (Silver Spring)*. 1631:28. [PubMed](#)
93. Zhang Z, *et al.* 2018. *Nat Med*. 24:617. [PubMed](#)
94. Parigi SM, *et al.* 2018. *Sci Rep*. 0.440277778. [PubMed](#)
95. Hoffmann FM, *et al.* 2018. *Front Immunol*. 9:1046. [PubMed](#)
96. Rebouças A, *et al.* 2021. *Microorganisms*. 9.: [PubMed](#)
97. Rigo MM, *et al.* 2020. *FEBS J*. .: [PubMed](#)
98. Li J, *et al.* 2021. *Front Immunol*. 12:710406. [PubMed](#)
99. Wikstrom M, *et al.* 2006. *J Immunol*. 177:913. [PubMed](#)
100. Kim D, *et al.* 2019. *Immune Netw*. 19:e32. [PubMed](#)
101. Kawabe T, *et al.* 2017. *Sci Immunol*. 2:eaam9315. [PubMed](#)
102. Dahlgren MW *et al.* 2019. *Immunity*. 50(3):707-722 . [PubMed](#)
103. Nagatake T, *et al.* 2018. *J Allergy Clin Immunol*. 142:470. [PubMed](#)
104. Seo SU, *et al.* 2021. *Front Immunol*. 12:697162. [PubMed](#)
105. Calderon B, *et al.* 2015. *J Exp Med*. 212: 1497-1512. [PubMed](#)
106. Keerthivasan S, *et al.* 2021. *Immunity*. 54(7):1511-1526.e8. [PubMed](#)
107. Hammer A, *et al.* 2017. *Front Immunol*. . 10.3389/fimmu.2017.01922. [PubMed](#)
108. Akiel M, *et al.* 2017. *Cancer Res*. 77:4014. [PubMed](#)
109. von Roemeling CA, *et al.* 2020. *Nat Commun*. 11:1508. [PubMed](#)
110. Cá B, *et al.* 2019. *Front Microbiol*. 1.876388889. [PubMed](#)
111. Eisenach P, *et al.* 2010. *J Cell Sci*. 123:4182. [PubMed](#)
112. Scortegagna M, *et al.* 2020. *Nat Commun*. 11:99. [PubMed](#)
113. Brownlie D, *et al.* 2021. *J Immunother Cancer*. 9.: [PubMed](#)
114. García G, *et al.* 2020. *Am J Pathol*. 844:190. [PubMed](#)
115. Leppin K, *et al.* 2014. *Invest Ophthalmol Vis Sci* . 55:3603. [PubMed](#)
116. Benson M, *et al.* 2007. *J Exp Med*. 204:1765. [PubMed](#)
117. Simmons S *et al.* 2019. *Elife*. 8 pii: e41239. [PubMed](#)
118. Van Der Zande HJP, *et al.* 2021. *FASEB J*. 35:e21331. [PubMed](#)
119. Xu W, *et al.* 2021. *Immunity*. 54(3):526-541.e7. [PubMed](#)
120. Goltsev Y *et al.* 2018. *Cell*. 174(4):968-981 . [PubMed](#)
121. Satoh-Takayama N, *et al.* 2020. *Immunity*. 52(4):635-649. [PubMed](#)
122. Fitzpatrick Z, *et al.* 2020. *Nature*. 587:472. [PubMed](#)
123. Pushalkar S, *et al.* 2018. *Cancer Discov*. 0.613194444. [PubMed](#)
124. Danne C *et al.* 2017. *Cell host & microbe*. 22(6):733-745 . [PubMed](#)
125. Chen B, *et al.* 2021. *Cell*. 184:6262. [PubMed](#)
126. An Y *et al.* 2018. *Cell reports*. 25(3):702-714 . [PubMed](#)
127. Hung LY, *et al.* 2019. *J Immunol*. 203:511. [PubMed](#)
128. Rios-Doria J, *et al.* 2017. *Cancer Res*. 77:2686. [PubMed](#)
129. Kikuchi K, *et al.* 2018. *J Immunol*. 201:635. [PubMed](#)
130. Khameneh HJ, *et al.* 2017. *J Immunol*. 198:196. [PubMed](#)
131. Song M, *et al.* 2020. *Nat Commun*. 11:6298. [PubMed](#)
132. Fritz Y, *et al.* 2017. *J Invest Dermatol*. 137:696. [PubMed](#)
133. Ito Y, *et al.* 2018. *J Exp Med*. 215:2617. [PubMed](#)
134. Kästele V, *et al.* 2021. *Mucosal Immunol*. 14:717. [PubMed](#)
135. Prabakaran T, *et al.* 2021. *EBioMedicine*. 66:103314. [PubMed](#)

RRID

AB_313770 (BioLegend Cat. No. 117301)
 AB_313771 (BioLegend Cat. No. 117302)

Antigen Details

Structure

Integrin α -chain, associates with integrin β_2 (CD18), 150 kD

Distribution

Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells

Function	Cellular adhesion
Ligand/Receptor	iC3b, fibrinogen
Cell Type	Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen Facts Book Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol.</i> 156:3780.
Gene ID	16411


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

Product Data



C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and purified N418 (top) or purified Armenian hamster IgG isotype control (bottom), followed by anti-Armenian hamster IgG FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all

applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587